These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 29688312)

  • 1. A prospective 5-year follow-up after population-based systematic screening for atrial fibrillation.
    Engdahl J; Holmén A; Rosenqvist M; Strömberg U
    Europace; 2018 Nov; 20(FI_3):f306-f311. PubMed ID: 29688312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.
    Martinez C; Katholing A; Wallenhorst C; Freedman SB
    Thromb Haemost; 2016 Jan; 115(1):31-9. PubMed ID: 26246112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study.
    Svennberg E; Engdahl J; Al-Khalili F; Friberg L; Frykman V; Rosenqvist M
    Circulation; 2015 Jun; 131(25):2176-84. PubMed ID: 25910800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure.
    Savarese G; Sartipy U; Friberg L; Dahlström U; Lund LH
    Heart; 2018 Jul; 104(13):1093-1100. PubMed ID: 29371374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the Quality of Anticoagulant Prescribed for Patients With Atrial Fibrillation at the St John of God Hawkesbury District Health Centre, New South Wales, Australia.
    Wertheimer G; Bereznicki LR
    J Cardiovasc Pharmacol Ther; 2019 Jan; 24(1):46-53. PubMed ID: 29962220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flaws in Anticoagulation Strategies in Patients With Atrial Fibrillation at Hospital Discharge.
    Kartas A; Samaras A; Vasdeki D; Dividis G; Fotos G; Paschou E; Forozidou E; Tsoukra P; Kotsi E; Goulas I; Efthimiadis G; Karvounis H; Tzikas A; Giannakoulas G
    J Cardiovasc Pharmacol Ther; 2019 May; 24(3):225-232. PubMed ID: 30599759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and management of atrial fibrillation by primary care physicians in Italy : a retrospective, observational analysis.
    Piccinocchi G; Laringe M; Guillaro B; Arpino G; Piccinocchi R; Nigro G; Calabrò P
    Clin Drug Investig; 2012 Nov; 32(11):771-7. PubMed ID: 23018284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Patients With Atrial Fibrillation Newly Recommended for Oral Anticoagulation Under the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society Guideline.
    Gray MP; Saba S; Zhang Y; Hernandez I
    J Am Heart Assoc; 2018 Jan; 7(1):. PubMed ID: 29301756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in Atrial Fibrillation and Prescription of Oral Anticoagulants and Embolic Strokes in Germany.
    Guelker JE; Bufe A; Klues H; Shin DI; Blockhaus C; Gabriel NH; Haverkamp W; Kroeger K
    Cardiovasc Revasc Med; 2019 May; 20(5):399-402. PubMed ID: 30115560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation.
    Perino AC; Fan J; Askari M; Heidenreich PA; Keung E; Raitt MH; Piccini JP; Ziegler PD; Turakhia MP
    Circulation; 2019 May; 139(22):2502-2512. PubMed ID: 30880434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry.
    Lip GY; Laroche C; Popescu MI; Rasmussen LH; Vitali-Serdoz L; Dan GA; Kalarus Z; Crijns HJ; Oliveira MM; Tavazzi L; Maggioni AP; Boriani G
    Europace; 2015 Dec; 17(12):1777-86. PubMed ID: 26321406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Influencing Oral Anticoagulation Prescription for Patients Presenting to Emergency Departments With Atrial Fibrillation and Flutter.
    Miller RJH; Chew DS; Rezazadeh S; Klassen S; Pournazari P; Lang E; Quinn FR
    Can J Cardiol; 2018 Jun; 34(6):804-807. PubMed ID: 29801744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rates and Determinants for the Use of Anticoagulation Treatment before Stroke in Patients with Known Atrial Fibrillation.
    Giustozzi M; Agnelli G; Quattrocchi S; Acciarresi M; Alberti A; Caso V; Vedovati MC; Venti M; Paciaroni M
    Cerebrovasc Dis Extra; 2020; 10(2):44-49. PubMed ID: 32375143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stepwise mass screening for atrial fibrillation using N-terminal pro b-type natriuretic peptide: the STROKESTOP II study design.
    Engdahl J; Svennberg E; Friberg L; Al-Khalili F; Frykman V; Kemp Gudmundsdottir K; Fredriksson T; Rosenqvist M
    Europace; 2017 Feb; 19(2):297-302. PubMed ID: 28011798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thromboembolic risk and effect of oral anticoagulation according to atrial fibrillation patterns: A systematic review and meta-analysis.
    Lilli A; Di Cori A; Zacà V
    Clin Cardiol; 2017 Sep; 40(9):641-647. PubMed ID: 28471498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between atrial fibrillation, anticoagulation, risk of cerebrovascular events and multimorbidity in general practice: a registry-based study.
    Vanbeselaere V; Truyers C; Elli S; Buntinx F; De Witte H; Degryse J; Henrard S; Vaes B
    BMC Cardiovasc Disord; 2016 Mar; 16():61. PubMed ID: 27021333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme.
    Proietti M; Mairesse GH; Goethals P; Scavee C; Vijgen J; Blankoff I; Vandekerckhove Y; Lip GY;
    Europace; 2016 Dec; 18(12):1779-1786. PubMed ID: 27170000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
    Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
    Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-permanent atrial fibrillation and oral anticoagulant therapy are related to survival during 10years after first-ever ischemic stroke.
    Baturova MA; Lindgren A; Carlson J; Shubik YV; Bertil Olsson S; Platonov PG
    Int J Cardiol; 2017 Apr; 232():134-139. PubMed ID: 28132778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Underuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary Review.
    Hsu JC; Freeman JV
    Clin Pharmacol Ther; 2018 Aug; 104(2):301-310. PubMed ID: 29328506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.